BPC-157 + TB-500
in St. George, Utah

BPC-157 (Body Protective Compound 157) is a 15-amino-acid peptide derived from a protective protein found in human gastric juice. In research and clinical settings, it's been studied for promoting tissue regeneration, accelerating healing of tendons, ligaments, and muscle, supporting gut health and ulcer healing, and reducing inflammation. It works in part by promoting angiogenesis (new blood vessel formation in healing tissue) and modulating growth factor signaling.

TB-500 (Thymosin Beta-4) is a peptide that supports cellular migration, actin regulation, and tissue remodeling. While BPC-157 focuses on regeneration and inflammation, TB-500 supports the cellular machinery that moves new cells into damaged areas. Combined, they address overlapping but distinct phases of the healing cascade. Aera Medical Aesthetics commonly offers both in a paired protocol when patients have significant tissue injury or chronic inflammation.

BPC-157 is not an FDA-approved drug. Its regulatory status as a compounded peptide has shifted — in 2023, the FDA placed BPC-157 on Category 2 of the 503A compounding bulk substances list, restricting some compounding pharmacy preparation. As of this page's last update, BPC-157 remains available through some 503A pharmacies under a valid prescription, but availability and supply are not guaranteed. Janessa will tell you the current status of supply at your consultation. We do not work with research-only or gray-market peptide suppliers.

Patients use BPC-157 most commonly for: tendinopathy and ligament injury (rotator cuff, Achilles, patellar tendon, lateral epicondylitis), joint pain from osteoarthritis or overuse, post-surgical recovery to support tissue healing, gastrointestinal inflammation including ulcers and IBD-related inflammation, and chronic muscle injury that hasn't responded to rest and physical therapy. It is not a replacement for proper rehab or surgery when those are indicated — it's a supportive treatment within a broader plan.

Most commonly subcutaneous injection (similar to insulin pens) administered daily. Some protocols include injection directly near the injury site for tendon or joint work, performed by Janessa in-office. Treatment cycles typically run 4–6 weeks, with cycles repeated as needed. We teach proper at-home injection technique at the start of therapy.

At Aera Medical Aesthetics, BPC-157 cycles typically run $400–$600 for a 4–6 week course including the peptide, injection supplies, and follow-up. Combined BPC-157 + TB-500 protocols are typically $600–$900 for the same duration. The exact price depends on dosing protocol and current pharmacy pricing. Call (435) 319-4064 for current pricing.

For acute tissue injury (recent tendon strain, post-surgical), patients typically report meaningful improvement at 2–4 weeks. For chronic conditions (osteoarthritis, long-standing tendinopathy), improvement is typically gradual over 4–8 weeks with cycles repeated. Some patients respond strongly; others modestly. Honest expectation-setting is part of the consultation.

BPC-157 is generally well-tolerated in clinical and research settings. Most-common side effects: injection-site redness or mild irritation, occasional fatigue, rarely mild GI upset. No major safety signals have been identified at standard doses, but long-term human safety data is limited. Patients with active cancer, certain autoimmune conditions, or pregnancy should not use BPC-157.

Patients with active or recent cancer (BPC-157's effect on angiogenesis could theoretically support tumor growth), pregnant or breastfeeding patients, patients with serious autoimmune conditions, and patients with severe organ disease. Janessa screens for contraindications during the consultation and reviews medical history fully before prescribing.